In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib.
We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety.
Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.
Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.
The oncologist. 2022 Dec 28 [Epub ahead of print]
Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini
Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA., Department of Medical Oncology, Gustave Roussy, Villejuif, France., Department of Hematology and Medical Oncology, Texas A&M University College of Medicine, Bryan, TX, USA., Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro and Policlinico Consorziale di Bari, Bari, Italy., Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Clinical Development and Medical Affairs, Aveo Oncology, Boston, MA, USA., Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.